Kristina Burow - 27 Oct 2025 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: NMRA
Reported as of: 27 Oct 2025
Net transaction value: +$4,999,977
SEC form: 4
Accepted by SEC: 29 Oct 2025, 19:22:24 UTC
Prior SEC filing: 23 Jun 2025
Next SEC filing: 13 Nov 2025
Source filing: View source filing
Reporting owner signature: Kristina Burow, Managing Director, By: /s/ Mark McDonnell, as Attorney-in-Fact

Key filing fact

Kristina Burow filed Form 4 for Neumora Therapeutics, Inc. (NMRA) on 29 Oct 2025.

Key facts

This page summarizes Kristina Burow's Form 4 filing for Neumora Therapeutics, Inc. (NMRA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 29 Oct 2025, 19:22.

Change

Previous filing in this sequence was filed on 23 Jun 2025.
Current net transaction value: +$4,999,977.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001569248 Primary reporting owner

Burow Kristina

Relationship: Director, 10%+ Owner
Address: 8755 W. HIGGINS ROAD,SUITE 1025, CHICAGO
Signature: Kristina Burow, Managing Director, By: /s/ Mark McDonnell, as Attorney-in-Fact
Signature date: 29 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NMRA transaction

Common Stock

Purchase

Transaction value: $4,999,977
Shares: +1,915,700
Change %: +46%
Price: $2.61
Shares after: 6,046,907
Date: 27 Oct 2025
Ownership: By ARCH Venture Fund XII, L.P.
Footnotes: F1

NMRA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,387,228
Date: 27 Oct 2025
Ownership: By ARCH Venture Fund VII, L.P.
Footnotes: F2

NMRA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,321,566
Date: 27 Oct 2025
Ownership: By ARCH Venture Fund VIII Overage, L.P.
Footnotes: F3

NMRA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 12,205,379
Date: 27 Oct 2025
Ownership: By ARCH Venture Fund X, L.P.
Footnotes: F4, F6

NMRA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 11,886,758
Date: 27 Oct 2025
Ownership: By ARCH Venture Fund X Overage, L.P.
Footnotes: F5, F6

NMRA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 47,717
Date: 27 Oct 2025
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Represents shares held directly by ARCH Venture Fund XII, L.P. (ARCH XII). ARCH Venture Partners XII, L.P. (AVP XII LP) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (AVP XII LLC) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the AVP XII LLC Committee Members). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

Footnote F2

Represents shares held directly by ARCH Venture Fund VII, L.P. (ARCH VII). ARCH Venture Partners VII, L.P. (AVP VII LP) is the sole general partner of ARCH VII, and ARCH Venture Partners VII, LLC (AVP VII LLC) is the sole general partner of AVP VII LP. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VII LLC (AVP VII LLC Managing Directors). AVP VII LP and AVP VII LLC may be deemed to beneficially own the shares held by ARCH VII, and each of the AVP VII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VII. Each of AVP VII LP, AVP VII LLC and the AVP VII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

Footnote F3

Represents shares held directly by ARCH Venture Fund VIII Overage, L.P. (ARCH VIII Overage). ARCH Venture Partners VIII, LLC (AVP VIII LLC) is the general partner of ARCH VIII Overage. Clinton Bybee, Keith Crandell and Robert Nelsen are the managing directors of AVP VIII LLC (the AVP VIII LLC Managing Directors). AVP VIII LLC may be deemed to beneficially own the shares held by ARCH VIII Overage, and each of the AVP VIII LLC Managing Directors may be deemed to share the power to direct the disposition and vote of the shares held by ARCH VIII Overage. Each of AVP VIII LLC and the AVP VIII LLC Managing Directors disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.

Footnote F4

Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X.

Footnote F5

Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.

Footnote F6

ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC and the AVP X Committee Members disclaims beneficial ownership of such shares except to the extent of their pecuniary interest therein, if any.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .